Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maria Soloviev
Institution:
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
Massachusetts Eye and Ear Infirmary,
Harvard University,
EMD Serono, Inc. (United States),
Merck Healthcare KGaA, Darmstadt (Germany)
ORCID:
0009-0000-6439-8386
Observed ORCID:
0009-0000-6439-8386
OpenAlex ID:
A5039445057
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
2022
·
Yan Lan
, Tsz-Lun Yeung
, et al.
·
Journal for ImmunoTherapy of Cancer
·
57
PDF
Mpp4 is required for proper localization of plasma membrane calcium ATPases and maintenance of calcium homeostasis at the rod photoreceptor synaptic terminals
2007
·
Jun Yang
, Basil Pawlyk
, et al.
·
Human Molecular Genetics
·
39
Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule
2012
·
Christie Kelton
, John S. Wesolowski
, et al.
·
Archives of Biochemistry and Biophysics
·
24
Effects of Low AIPL1 Expression on Phototransduction in Rods
2006
·
Clint L. Makino
, Xiao-Hong Wen
, et al.
·
Investigative Ophthalmology & Visual Science
·
22
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies
2023
·
Samantha M. Goodstal
, Jing Lin
, et al.
·
Scientific Reports
·
11
PDF
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2023
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
·
Cancer Immunology Research
·
7
M5542, a bifunctional fusion protein targeting CD80, CD86, and OX40L that modulates excessive T-cell activity: a preclinical proof-of-concept study
2026
·
Michelle Downing
, Allison Christiaansen
, et al.
·
Frontiers in Immunology
PDF
Data from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S4 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S14 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S13 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S13 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S3 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S5 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S2 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S11 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S12 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S10 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S8 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Supplementary Tables from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S9 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S7 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S9 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Show more works
View as search
Works count:
32
Citation count:
160
H-index:
6
I10-index:
5
Year
Topic
Type